FBXL17

Across TCGA pan-cancer cohorts, FBXL17 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of FBXL17’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where FBXL17 RNA is repressed in tumor relative to normal tissue. In most cancer types FBXL17 is over-expressed in tumor, although a few such as THCA and LUSC show the opposite, repressed pattern.

THCA, LUSC, and COAD are the cancer types where FBXL17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FBXL17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.848	<.001	10	view →
LUSC	Male	III,IV	−1.172	<.001	9	view →
COAD	All	All	−0.478	<.001	8	view →
BLCA	All	IV	−0.654	.009	7	view →
UCEC	All	All	−1.110	<.001	6	view →
KIRC	All	All	−0.221	.008	6	view →
LIHC	Male	All	+0.581	<.001	5	view →
HNSC	All	All	−0.337	.003	5	view →
LUAD	Female	II,III,IV	−0.451	.002	4	view →
BRCA	Female	All	−0.353	<.001	4	view →
CHOL	All	All	+0.778	.001	2	view →
READ	All	All	−0.588	.018	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

FBXL17–THCA

Open the THCA breakdown →